{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:57Z","timestamp":1792784877743,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KTN\/BBSRC CASE Studentship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recombinant adeno-associated virus (rAAV) shows great promise for gene therapy, however scalability, yield and quality remain significant issues. Here we describe an rAAV manufacturing strategy using a \u2018helper\u2019 adenovirus that self-inhibits its major late promoter (MLP) to truncate its own replication. Inserting a tetracycline repressor (TetR) binding site into the MLP and encoding the TetR under its transcriptional control allowed normal adenovirus replication in the presence of doxycycline but only genome amplification and early gene expression (the \u2018helper\u2019 functions) in its absence. Using this self-inhibiting adenovirus we demonstrate delivery of adenoviral helper functions, AAV rep and cap genes, and the rAAV genome to yield up to 30-fold more rAAV vectors compared to the helper-free plasmid approach and significant improvements in particle infectivity for a range of serotypes. This system allows significant improvements in the production of serotypes rAAV2, rAAV6, rAAV8 and rAAV9, and enables propagation of existing rAAV without transfection, a process that improves batch quality by depleting reverse packaged DNA contaminants. We propose this as a high-yielding, contaminant-free system suitable for scalable rAAV manufacture.<\/jats:p>","DOI":"10.1038\/s41467-022-28738-2","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:06:11Z","timestamp":1646633171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination"],"prefix":"10.1038","volume":"13","author":[{"given":"Weiheng","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-1400","authenticated-orcid":false,"given":"Maria I.","family":"Patr\u00edcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-6341","authenticated-orcid":false,"given":"Jakub M.","family":"Krakowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0841","authenticated-orcid":false,"given":"Leonard W.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Cawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"28738_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li, C. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 1\u201318 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"28738_CR2","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","volume":"72","author":"X Xiao","year":"1998","unstructured":"Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224\u20132232 (1998).","journal-title":"J. Virol."},{"key":"28738_CR3","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","volume":"3","author":"N Clement","year":"2016","unstructured":"Clement, N. & Grieger, J. C. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol. Ther. Methods Clin. Dev. 3, 16002 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28738_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jgm.622","volume":"6","author":"D Farson","year":"2004","unstructured":"Farson, D. et al. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 6, 1369\u20131381 (2004).","journal-title":"J. Gene Med."},{"key":"28738_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/hgtb.2013.046","volume":"24","author":"J Martin","year":"2013","unstructured":"Martin, J. et al. Generation and characterization of AAV producer cell lines for research and preclinical vector production. Hum. Gene Ther. Methods 24, 253\u2013269 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"28738_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/hum.2009.070","volume":"20","author":"BA Thorne","year":"2009","unstructured":"Thorne, B. A., Takeya, R. K. & Peluso, R. W. Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 20, 707\u2013714 (2009).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1523-1755.2002.0610s1009.x","volume":"61","author":"KR Clark","year":"2002","unstructured":"Clark, K. R. Recent advances in recombinant adeno-associated virus vector production. Kidney Int. 61, 9\u201316 (2002).","journal-title":"Kidney Int."},{"key":"28738_CR8","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1128\/jvi.63.12.5124-5132.1989","volume":"63","author":"P Jansen-Durr","year":"1989","unstructured":"Jansen-Durr, P., Mondesert, G. & Kedinger, C. Replication-dependent activation of the adenovirus major late promoter is mediated by the increased binding of a transcription factor to sequences in the first intron. J. Virol. 63, 5124\u20135432 (1989).","journal-title":"J. Virol."},{"key":"28738_CR9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","volume":"7","author":"X Danthinne","year":"2000","unstructured":"Danthinne, X. & Imperiale, M. J. Production of first generation adenovirus vectors: a review. Gene Ther. 7, 1707\u20131714 (2000).","journal-title":"Gene Ther."},{"key":"28738_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0169-409X(93)90059-D","volume":"12","author":"CT Bruce","year":"1993","unstructured":"Bruce, C. T. Adenoviral vectors for gene transfer. Adv. Drug Deliv. Rev. 12, 185\u2013199 (1993).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"28738_CR11","first-page":"213","volume":"272","author":"CSH Young","year":"2003","unstructured":"Young, C. S. H. The structure and function of the adenovirus major late promoter. Curr. Top. Microbiol. Immunol. 272, 213\u2013249 (2003).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"28738_CR12","first-page":"1091","volume":"7","author":"LJ Brunet","year":"1987","unstructured":"Brunet, L. J., Babiss, L. E., Young, C. S. H. & Mills, D. R. Mutation in the adenovirus major late promoter: effects on viability and transcription during infection. Mol. Cell Biol. 7, 1091\u20131100 (1987).","journal-title":"Mol. Cell Biol."},{"key":"28738_CR13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/nar\/26.5.1240","volume":"26","author":"EJ Parker","year":"1998","unstructured":"Parker, E. J., Botting, C. H., Webster, A. & Hay, R. T. Adenovirus DNA polymerase: domain organisation and interaction with preterminal protein. Nucleic Acids Res. 26, 1240\u20131247 (1998).","journal-title":"Nucleic Acids Res."},{"key":"28738_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1126\/science.7792603","volume":"268","author":"M Gossen","year":"1995","unstructured":"Gossen, M. et al. Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766\u20131769 (1995).","journal-title":"Science"},{"key":"28738_CR15","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1093\/nar\/gkq1258","volume":"39","author":"TG Uil","year":"2011","unstructured":"Uil, T. G. et al. Directed adenovirus evolution using engineered mutator viral polymerases. Nucleic Acids Res. 39, e30 (2011).","journal-title":"Nucleic Acids Res."},{"key":"28738_CR16","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1128\/JVI.72.5.4049-4056.1998","volume":"72","author":"SP Fessler","year":"1998","unstructured":"Fessler, S. P. & Young, C. S. Control of adenovirus early gene expression during the late phase of infection. J. Virol. 72, 4049\u20134056 (1998).","journal-title":"J. Virol."},{"key":"28738_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jviromet.2004.02.003","volume":"118","author":"G Maheshwari","year":"2004","unstructured":"Maheshwari, G., Jannat, R., McCormick, L. & Hsu, D. Thermal inactivation of adenovirus type 5. J. Virol. Methods 118, 141\u2013146 (2004).","journal-title":"J. Virol. Methods"},{"key":"28738_CR18","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1089\/hum.1996.7.17-2079","volume":"7","author":"KJ Fisher","year":"1996","unstructured":"Fisher, K. J., Kelley, W. M., Burda, J. F. & Wilson, J. M. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 7, 2079\u20132087 (1996).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000024980","volume":"42","author":"SA Afione","year":"1999","unstructured":"Afione, S. A., Wang, J., Walsh, S., Guggino, W. B. & Flotte, T. R. Delayed expression of adeno-associated virus vector DNA. Intervirology 42, 213\u2013220 (1999).","journal-title":"Intervirology"},{"key":"28738_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.gt.3300807","volume":"6","author":"XL Liu","year":"1999","unstructured":"Liu, X. L., Clark, K. R. & Johnson, P. R. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6, 293\u2013299 (1999).","journal-title":"Gene Ther."},{"key":"28738_CR21","doi-asserted-by":"publisher","first-page":"14294","DOI":"10.1073\/pnas.1102883108","volume":"108","author":"V Sitaraman","year":"2011","unstructured":"Sitaraman, V. et al. Computationally designed adeno-associated virus (AAV) Rep 78 is efficiently maintained within an adenovirus vector. Proc. Natl Acad. Sci. USA 108, 14294\u201314299 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28738_CR22","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1128\/JVI.03120-15","volume":"90","author":"S Weger","year":"2016","unstructured":"Weger, S., Hammer, E., Gonsior, M., Stutika, C. & Heilbronn, R. A regulatory element near the 3\u2032 end of the adeno-associated virus rep gene inhibits adenovirus replication in cis by means of p40 promoter-associated short transcripts. J. Virol. 90, 3981\u20133993 (2016).","journal-title":"J. Virol."},{"key":"28738_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1006\/viro.2001.1192","volume":"291","author":"X-J Jing","year":"2001","unstructured":"Jing, X.-J., Kalman-Maltese, V., Cao, X., Yang, Q. & Trempe, J. P. Inhibition of adenovirus cytotoxicity, replication, and E2a gene expression by adeno-associated virus. Virology 291, 140\u2013151 (2001).","journal-title":"Virology"},{"key":"28738_CR24","first-page":"2982","volume":"62","author":"RB Batchu","year":"2002","unstructured":"Batchu, R. B. et al. Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. Cancer Res. 62, 2982\u20132985 (2002).","journal-title":"Cancer Res."},{"key":"28738_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1006\/viro.2001.1286","volume":"293","author":"S Nada","year":"2002","unstructured":"Nada, S. & Trempe, J. P. Characterization of adeno-associated virus rep protein inhibition of adenovirus E2a gene expression. Virology 293, 345\u2013355 (2002).","journal-title":"Virology"},{"key":"28738_CR26","doi-asserted-by":"publisher","first-page":"7807","DOI":"10.1128\/JVI.00198-06","volume":"80","author":"JM Timpe","year":"2006","unstructured":"Timpe, J. M., Verrill, K. C. & Trempe, J. P. Effects of adeno-associated virus on adenovirus replication and gene expression during coinfection. J. Virol. 80, 7807\u20137815 (2006).","journal-title":"J. Virol."},{"key":"28738_CR27","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.1128\/jvi.69.11.6880-6885.1995","volume":"69","author":"C H\u00f6lscher","year":"1995","unstructured":"H\u00f6lscher, C., Kleinschmidt, J. A. & B\u00fcrkle, A. High-level expression of adeno-associated virus (AAV) Rep78 or Rep68 protein is sufficient for infectious-particle formation by a rep-negative AAV mutant. J. Virol. 69, 6880\u20136885 (1995).","journal-title":"J. Virol."},{"key":"28738_CR28","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1128\/JVI.00183-06","volume":"80","author":"PG Needham","year":"2006","unstructured":"Needham, P. G. et al. Adeno-associated virus rep protein-mediated inhibition of transcription of the adenovirus major late promoter in vitro. J. Virol. 80, 6207\u20136217 (2006).","journal-title":"J. Virol."},{"key":"28738_CR29","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1128\/jvi.71.7.5236-5243.1997","volume":"71","author":"J Li","year":"1997","unstructured":"Li, J., Samulski, R. J. & Xiao, X. Role for highly regulated rep gene expression in adeno associated virus vector production. J. Virol. 71, 5236\u20135243 (1997).","journal-title":"J. Virol."},{"key":"28738_CR30","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1128\/jvi.63.8.3479-3488.1989","volume":"63","author":"L-S Chang","year":"1989","unstructured":"Chang, L.-S., Shi, Y. & Shenk, T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 63, 3479\u20133488 (1989).","journal-title":"J. Virol."},{"key":"28738_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1099\/vir.0.026542-0","volume":"92","author":"C Rauschhuber","year":"2011","unstructured":"Rauschhuber, C., Wolf, A. & Ehrhardt, A. Transcriptional activity of inverted terminal repeats of various human adenovirus serotypes. J. Gen. Virol. 92, 669\u2013674 (2011).","journal-title":"J. Gen. Virol."},{"key":"28738_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0042-6822(89)90227-4","volume":"173","author":"N Chejanovsky","year":"1989","unstructured":"Chejanovsky, N. & Carter, B. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology 173, 120\u2013128 (1989).","journal-title":"Virology"},{"key":"28738_CR33","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1093\/emboj\/20.12.3282","volume":"20","author":"JA King","year":"2001","unstructured":"King, J. A., Dubielzig, R., Grimm, D. & Kleinschmidt, J. A. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 20, 3282\u20133291 (2001).","journal-title":"EMBO J."},{"key":"28738_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/mt.2015.187","volume":"24","author":"JC Grieger","year":"2016","unstructured":"Grieger, J. C., Soltys, S. M. & Samulski, R. J. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol. Ther. 24, 287\u2013297 (2016).","journal-title":"Mol. Ther."},{"key":"28738_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1089\/hum.2013.184","volume":"25","author":"M Mietzsch","year":"2014","unstructured":"Mietzsch, M. et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum. Gene Ther. 25, 212\u2013222 (2014).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/hgtb.2018.228","volume":"30","author":"B Strobel","year":"2019","unstructured":"Strobel, B. et al. Standardized, scalable, and timely flexible adeno-associated virus vector production using frozen high-density HEK-293 cell stocks and CELLdiscs. Hum. Gene Ther. Methods 30, 23\u201333 (2019).","journal-title":"Hum. Gene Ther. Methods"},{"key":"28738_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.omtm.2018.07.004","volume":"10","author":"A Francois","year":"2018","unstructured":"Francois, A. et al. Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls. Mol. Ther. Methods Clin. Dev. 10, 223\u2013236 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"28738_CR38","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani, A. C. et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107, 2653\u20132661 (2006).","journal-title":"Blood"},{"key":"28738_CR39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ymthe.2005.06.003","volume":"12","author":"G Chadeuf","year":"2005","unstructured":"Chadeuf, G., Ciron, C., Moullier, P. & Salvetti, A. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744\u2013753 (2005).","journal-title":"Mol. Ther."},{"key":"28738_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1743-422X-10-74","volume":"10","author":"BL Ellis","year":"2013","unstructured":"Ellis, B. L. et al. A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol. J. 10, 74 (2013).","journal-title":"Virol. J."},{"key":"28738_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2144\/000114170","volume":"56","author":"K Petri","year":"2014","unstructured":"Petri, K. et al. Comparative next-generation sequencing of adeno-associated virus inverted terminal repeats. Biotechniques 56, 269\u2013273 (2014).","journal-title":"Biotechniques"},{"key":"28738_CR42","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5\u2013factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519\u20132530 (2017).","journal-title":"N. Engl. J. Med."},{"key":"28738_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","volume":"6","author":"AM Keeler","year":"2019","unstructured":"Keeler, A. M. & Flotte, T. R. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Ann. Rev. Virol. 6, 601\u2013621 (2019).","journal-title":"Ann. Rev. Virol."},{"key":"28738_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","volume":"20","author":"DE Bowles","year":"2012","unstructured":"Bowles, D. E. et al. Phase 1 gene therapy for duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443\u2013455 (2012).","journal-title":"Mol. Ther."},{"key":"28738_CR45","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1089\/hum.2009.064","volume":"20","author":"JF Wright","year":"2009","unstructured":"Wright, J. F. Transient transfection methods for clinical adeno-associated viral vector production. Hum. Gene Ther. 20, 698\u2013706 (2009).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1425-0","volume":"8","author":"H-H Huang","year":"2015","unstructured":"Huang, H.-H., Seeger, C., Danielson, U. H. & Lindblad, P. Analysis of the leakage of gene repression by an artificial TetR-regulated promoter in cyanobacteria. BMC Res. Notes 8, 459 (2015).","journal-title":"BMC Res. Notes"},{"key":"28738_CR47","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00253-017-8670-1","volume":"102","author":"JJ Aponte-Ubillus","year":"2018","unstructured":"Aponte-Ubillus, J. J. et al. Molecular design for recombinant adeno-associated virus (rAAV) vector production. Appl. Microbiol. Biot. 102, 1045\u20131054 (2018).","journal-title":"Appl. Microbiol. Biot."},{"key":"28738_CR48","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/hum.2010.241","volume":"22","author":"Z Yuan","year":"2011","unstructured":"Yuan, Z., Qiao, C., Hu, P., Li, J. & Xiao, X. A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther. 22, 613\u2013624 (2011).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR49","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1128\/JVI.76.4.1904-1913.2002","volume":"76","author":"C Qiao","year":"2002","unstructured":"Qiao, C., Li, J., Skold, A., Zhang, X. & Xiao, X. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J. Virol. 76, 1904\u20131913 (2002).","journal-title":"J. Virol."},{"key":"28738_CR50","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/sj.gt.3300946","volume":"6","author":"D Grimm","year":"1999","unstructured":"Grimm, D. et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322\u20131330 (1999).","journal-title":"Gene Ther."},{"key":"28738_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2018.05.001","volume":"10","author":"SM Crosson","year":"2018","unstructured":"Crosson, S. M., Dib, P., Smith, K. J. & Zolotukhin, S. Helper free production of laboratory grade AAV and purification by iodixanol density gradient centrifugation. Mol. Ther. - Methods Clin. Dev. 10, 1\u20137 (2018).","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"28738_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-15-28","volume":"15","author":"R Holehonnur","year":"2014","unstructured":"Holehonnur, R. et al. Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. BMC Neurosci. 15, 28 (2014).","journal-title":"BMC Neurosci."},{"key":"28738_CR53","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1089\/hum.2010.107","volume":"21","author":"LH Vandenberghe","year":"2010","unstructured":"Vandenberghe, L. H. et al. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum. Gene Ther. 21, 1251\u20131257 (2010).","journal-title":"Hum. Gene Ther."},{"key":"28738_CR54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/biomedicines2010080","volume":"2","author":"JF Wright","year":"2014","unstructured":"Wright, J. F. Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment. Biomedicines 2, 80\u201397 (2014).","journal-title":"Biomedicines"},{"key":"28738_CR55","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/sj.gt.3302615","volume":"12","author":"O-W Merten","year":"2005","unstructured":"Merten, O.-W., G\u00e9ny-Fiamma, C. & Douar, A. M. Current issues in adeno-associated viral vector production. Gene Ther. 12, S51\u2013S61 (2005).","journal-title":"Gene Ther."},{"key":"28738_CR56","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ymthe.2005.08.018","volume":"12","author":"E Kohlbrenner","year":"2005","unstructured":"Kohlbrenner, E. et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12, 1217\u20131225 (2005).","journal-title":"Mol. Ther."},{"key":"28738_CR57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.vaccine.2011.10.095","volume":"30","author":"CF Shen","year":"2012","unstructured":"Shen, C. F. et al. Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine 30, 300\u2013306 (2012).","journal-title":"Vaccine"},{"key":"28738_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"28738_CR59","doi-asserted-by":"publisher","first-page":"e1000440","DOI":"10.1371\/journal.ppat.1000440","volume":"5","author":"R Cawood","year":"2009","unstructured":"Cawood, R. et al. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog. 5, e1000440 (2009).","journal-title":"PLoS Pathog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28738-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:13:19Z","timestamp":1669288399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28738-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28738"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28738-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.S., M.I.P., J.M.K. and R.C. are employees of OXGENE. W.S., L.W.S. and R.C. are inventors on intellectual property related to this work. OXGENE is a company pursuing the development of TESSA for the commercial manufacture of rAAV. W.S. and R.C. have filed a patent application on the subject matter of this manuscript (PCT\/GB2018\/052083). M.R.D. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1182"}}